Immunogenic oncolysis by tigilanol tiglate

Jonathan G. Pol; Manuela Lizarralde-Guerrero; Guido Kroemer

doi:10.1080/2162402X.2024.2360230

Immunogenic oncolysis by tigilanol tiglate

Jonathan G. Pol, Manuela Lizarralde-Guerrero, Guido Kroemer

Research output: Contribution to journal › Comment/debate

Abstract

Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

Original language	English
Article number	2360230
Journal	OncoImmunology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2024.2360230
Publication status	Published - 1 Jan 2024

Keywords

Cancer immunosurveillance
immunogenic cell death
intratumor immunotherapy
oncolysis
tigilanol tiglate

Access to Document

10.1080/2162402X.2024.2360230

Cite this

@article{d9fd8358b37b47498d7411ea8de9ba34,

title = "Immunogenic oncolysis by tigilanol tiglate",

abstract = "Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.",

keywords = "Cancer immunosurveillance, immunogenic cell death, intratumor immunotherapy, oncolysis, tigilanol tiglate",

author = "Pol, {Jonathan G.} and Manuela Lizarralde-Guerrero and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

month = jan,

day = "1",

doi = "10.1080/2162402X.2024.2360230",

language = "English",

volume = "13",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Immunogenic oncolysis by tigilanol tiglate

AU - Pol, Jonathan G.

AU - Lizarralde-Guerrero, Manuela

AU - Kroemer, Guido

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

AB - Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

KW - Cancer immunosurveillance

KW - immunogenic cell death

KW - intratumor immunotherapy

KW - oncolysis

KW - tigilanol tiglate

UR - http://www.scopus.com/inward/record.url?scp=85194880585&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2024.2360230

DO - 10.1080/2162402X.2024.2360230

M3 - Comment/debate

C2 - 38812571

AN - SCOPUS:85194880585

SN - 2162-4011

VL - 13

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2360230

ER -

Immunogenic oncolysis by tigilanol tiglate

Abstract

Keywords

Access to Document

Other files and links

Cite this